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Background: We previously showed that the long-acting beta agonist (LABA) salmeterol
as inhalation powder or metered-dose inhaler improves lung-function parameters assessed by
impulse oscillometry (IOS) in 2- to 5-year-old children with reversible-airway disease within
15 minutes.
Objective: We studied 12- to 45-year-olds with mild persistent asthma in order to compare the
onset and extent of peripheral airway effects following the first dose and after 4 weeks dosing
with two inhaled corticosteroid (ICS)/LABA combinations: fluticasone propionate/salmeterol
115/21 and budesonide/formoterol 160/4.5.
Methods: Thirty subjects with mild persistent asthma using only an as-needed short-acting
beta-agonist (albuterol) who had at least a 40% change in integrated low-frequency reactance
postalbuterol were selected and randomized to receive either fluticasone propionate/salmeterol
or budesonide/formoterol (15 subjects each). We collected three to six IOS replicates at baseline, at 5, 20, 40, 60, 120, and 240 minutes postdose at randomization, and after 4 weeks of
twice-daily dosing. Blinded investigators calculated IOS frequency-dependent resistance and
reactance (R5–R20 and AX), indicative of small-airway dysfunction, and also estimated the
peripheral airway resistance (Rp) and peripheral airway compliance (Cp), using a respiratoryimpedance model.
Results: At randomization visits, onset of action was detected as early as 5 minutes (t-test,
P , 0.05) after fluticasone propionate/salmeterol by Cp, and within 5 minutes after budesonide/
formoterol by R5–R20, AX, Rp, and Cp. However, after 4 weeks of dosing, only Rp was significantly
different (from 60 to 120 minutes) after fluticasone propionate/salmeterol, while R5–R20, AX,
Rp, and Cp were not significantly different within 240 minutes after budesonide/formoterol.
Conclusion: These two ICS/LABA combinations initially improved the peripheral airway function of 12- to 45-year-old asthmatics significantly in about 5 minutes or less, as measured by
R5–R20, AX, Rp, and/or Cp. After regular dosing for 4 weeks, pre- to postdose differences in these
parameters had diminished significantly due to improved predose status of peripheral airways.
Single dosing with ICS/LABA combinations in mild persistent asthma improves small-airway
function, and the effect is maintained over a 12-hour interval by regular use for 4 weeks.
Keywords: asthma, ICS/LABA combination, impulse oscillometry parameters, lung-model
parameters, peripheral airway resistance, peripheral airway compliance

Introduction
Previous work has revealed a heretofore-unrecognized early effect, ie, in under
15 minutes, of Serevent (salmeterol xinafoate) from a Diskus (inhalation powder) and
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a metered-dose inhaler (MDI) in 2- to 5-year-old children
with reversible airflow obstruction, assessed by forced oscillation (IOS).1 They had been selected for that study based on
demonstrated brisk response to the short-acting beta agonist
(SABA) albuterol at screening. Statistically significant
changes in airway mechanics were evident at 5 minutes, augmenting over the subsequent 55 minutes, and sustained for the
next 8 hours, based on IOS measurements at 5, 30, 60, 120,
240, and 480 minutes after drug administration. The change
was more prominent with Serevent MDI at 5 and 30 minutes
in small airways, while that with Serevent Diskus was more
prominent in large airways at these time points. While such
rapid onset of action is comparable to reports of formoterol
onset of action in adults,2 it has not been shown that similar
early action of salmeterol can be detected by IOS in older
children and adults. Moreover, whether and how salmeterol
differs from formoterol in terms of central and peripheral
airway effects are as yet unanswered questions.
The present study’s objectives were to obtain IOS parameters, and also to estimate lung-component properties that
reflect small-airway dysfunction (both resistive and elastic
components), at baseline and after a single dose in order to
compare the onset of drug action. We hypothesized that measurements using current IOS hardware and software along
with recently implemented augmentation of measurement
techniques, ie, lung model-parameter estimation, would be
sensitive enough to detect an early response to Advair hydrofluoroalkane (HFA) MDI (fluticasone propionate/salmeterol
115/21) and provide evidence of improved small-airway
mechanics at time points comparable to those for Symbicort pressurized metered-dose inhaler (pMDI; budesonide/
formoterol 160/4.5). Furthermore, we asked to what extent
either or both inhaled corticosteroid (ICS)/long-acting beta
agonist (LABA) combinations would still produce early and
significant responses after 4 weeks of dosing, since a persistent beneficial effect on small-airway dysfunction would
support the earlier and regular use of these agents in patients
with mild persistent asthma.3

Methods
Protocol
The patients were 12–45 years old with mild persistent
asthma as defined by Global Initiative on Asthma/National
Institutes of Health guidelines. They were recruited either
from the clinic population of the Asthma and Allergy Center
of El Paso or through advertising at area colleges. They
had to have had at least a 1-year history of asthma requiring SABA (albuterol) as needed, with the addition of short
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courses of inhaled corticosteroids or oral corticosteroids
in the preceding year. Subjects with respiratory infections
within the prior 6 weeks, and those using inhaled and/or
systemic corticosteroids or leukotriene antagonists within the
previous month were excluded, as were those maintained on
controllers for .6 months in the prior year. Other excluded
medications included LABA or oral antihistamines within
24 hours of each visit. At screening, subjects were assessed by
routine IOS measures (three to four replicates) at baseline and
20 minutes after SABA HFA pMDI (up to six inhalations).
Those who manifested .40% decrease in IOS frequencydependent reactance (AX) were enrolled and scheduled for
randomization (to Advair or Symbicort) within 1–7 days. On
visit 2, two puffs of the study drug were administered and IOS
measurements performed, after which subjects were given
open-label supplies of either drug and instructed to inhale two
puffs twice a day for 4 weeks. To assure .80% compliance
with dosing, subjects were phoned every week, and their
drug canisters weighed. Finally, on visit 3, all measurements
undertaken on visit 2 were repeated. This study was conducted in accordance with the amended Declaration of
Helsinki, and the protocol was approved by the Chesapeake
IRB (Pro00002852) in June 2009; its ClinicalTrials.gov
identifier is NCT00867737.
On visits 2 and 3, a review of recent medical history
and measurement of vital signs were performed. Extended
baseline IOS measurements (six replicates) were followed
by dosing and serial IOS measurements over 240 minutes.
Heart rate and respiratory rate were recorded at 5, 20, 40,
60, 120, and 240 minutes; immediately after each of these
recordings, postdose IOS measurements (three replicates
each) were performed. For safety and reproducibility, drugs
were administered under supervision and subjects observed
while gargling immediately postdose.
Outcome measures (at each postdose time point)
included:
• IOS measures R5–R20 and AX
• model-derived estimates of large and small airways’
resistance and compliance.
The available IOS measures included AX and total respiratory system resistance R and reactance X at 3, 5, 10, 15,
20, and 25 Hz (R3, … R25; X3, … X25), which yielded
R5–R20. In addition, the twelve frequency-dependent R
and X measures were fitted to an equivalent electrical model
(analog) of the respiratory system to derive estimates of its
constituent resistance, inertance, and compliance values.
Paired t-tests compared each patient’s baseline IOS
AX and R5–R20 parameters, and each patient’s baseline
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large- and small-airway resistance and compliance estimates,
at visits 2 and 3, with the same at each postdose time point.
Statistical significance represented by P , 0.05 was used to
determine onset of action.

the IOS parameters as grouped by administered drug, visit
number, and time point. This same procedure was applied
to the aRIC model estimates of Rp and Cp.

Demographics

The mean values of R5–R20 and AX and of Rp, and Cp at
baseline and each postdose time point are shown in Table 1.
The results of paired t-tests comparing R5–R20 and AX at
each postdose time point to baseline values are plotted in
Figures 1 and 2, and those of comparing Rp and Cp at each
time point to baseline values in Figures 3 and 4.
For the randomization visits, onset of action was detected
from R5–R20 and AX (P , 0.05) between 5 and 20 minutes
after Advair and by 5 minutes after Symbicort, the effects
being uniformly sustained through 240 minutes by both
medications. During the final visits, onset of action was
detected from AX between 5 and 20 minutes after Advair and
was sustained up to 240 minutes, whereas no onset of action
could be detected post-Symbicort over 240 minutes.
From the model estimates, onset of action during the
randomization visits was detected by Cp between 5 and
20 minutes after Advair (P , 0.05), and by 5 minutes after
Symbicort (based on Cp and also Rp, P , 0.05), the effects
being uniformly sustained through 240 minutes by both
medications. During the final visits, onset of action was
detected from Rp between 40 and 60 minutes after Advair,
and this was sustained to between 120 and 240 minutes,
whereas no onset of action could be detected from Cp and
Rp post-Symbicort over 240 minutes.

Of 96 candidates screened, 31 were enrolled based on the
aforementioned criteria; informed written consent was
obtained from all patients for the treatment/testing and for
their medical data to be used in this study. However, one
subject withdrew, very early, so only 30 subjects completed
the study. Their demographics were: 15 male, 15 female, ages
12–45 (26.5 ± 11.5) years, height 142–181 (163.0 ± 9.6) cm,
and weight 32.5–150.2 (82.2 ± 23.2) kg. Advair or Symbicort
was randomly administered to 15 subjects each; the specific
drug assignment was not revealed to the data analysts until
they completed all IOS calculations and model-parameter
estimations.

Data analysis and modeling
The IOS parameters R5–R20 and AX, representing lowfrequency dependence of resistance4 and integrated low-frequency reactance area,5 respectively, were obtained directly
from the test readouts of all the 30 subjects; no adverse
events occurred, and all data were of sufficient quality and
consistency. With a little more effort, the respiratory system’s
aggregated small-airway resistance (Rp) and small-airway
compliance (Cp) were estimated assuming the augmented
RIC (aRIC) model,6 which also includes the large-airway
resistance (R) and inertance (I), and extrathoracic upperairway compliance (Ce); the estimates being those values
producing the best least-squares fit to the given (R3, … R25;
X3, … X25).6 Then, paired t-tests were applied to compare

Results

Discussion
We had hypothesized that Advair HFA MDI 115/21 would
produce an earlier than expected response in asthmatic

Table 1 Mean values of impulse oscillometry system frequency-dependent resistance (R5–R20; cmH2O/L/s) and reactance AX
(cmH2O/L), peripheral airway resistance (Rp; cmH2O/L/s), and peripheral airway compliance (Cp; L/cmH2O) at baseline (BL) and each
time point after administration of Advair or Symbicort during the randomization and final visits
Advair (randomization visit)
BL
R5–R20
AX
Rp
Cp

R5–R20
AX
Rp
Cp

5

20

Symbicort (randomization visit)

40

60

120

240

BL

40

60

120

240

0.204
0.159
0.126
1.526
1.122
0.774
0.547
0.503
0.423
0.084
0.114
0.138
Advair (final visit)

0.114
0.692
0.425
0.141

0.113
0.660
0.396
0.146

0.127
0.759
0.409
0.135

0.129
0.763
0.394
0.139

0.259
0.113
0.108
2.332
0.643
0.597
0.689
0.397
0.380
0.067
0.134
0.161
Symbicort (final visit)

0.112
0.663
0.403
0.143

0.097
0.554
0.372
0.152

0.096
0.537
0.356
0.162

0.098
0.536
0.359
0.163

BL

5

20

40

60

120

240

BL

5

20

40

60

120

240

0.164
1.171
0.472
0.115

0.135
0.841
0.429
0.130

0.119
0.663
0.406
0.141

0.111
0.613
0.387
0.150

0.118
0.594
0.372
0.147

0.118
0.606
0.361
0.147

0.123
0.687
0.405
0.139

0.127
0.833
0.426
0.136

0.101
0.571
0.406
0.166

0.094
0.551
0.399
0.165

0.099
0.554
0.385
0.161

0.099
0.545
0.370
0.163

0.096
0.526
0.350
0.168

0.096
0.529
0.364
0.169
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0.5

P

0.01

Advair (randomization visit)

0.4

0.009
0.008

0.35

0.007

0.45

0.3

0.006

0.25

P 0.005

0.2

0.004

0.15

0.003

0.1

0.002
0.001

0.05

Symbicort (randomization visit)

0

0
5

20

40

60

120

5

240

20

Time (minutes)

40

60

120

240

Time (minutes)

Figure 1 t-test P-values of impulse oscillometry parameters (frequency-dependent resistance [R5–R20], *, and reactance [AX], ) at each time point after administration
of Advair or Symbicort during randomization visits compared to the patients’ baseline R5–R20 and AX values (0.204 cmH2O/L/second and 1.526 cmH2O/L, respectively, for
Advair; 0.259 cmH2O/L/second, and 2.332 cmH2O/L, respectively, for Symbicort) during the same visit (n = 15 for each group).

teenagers and young adults, at times comparable to those for
Symbicort pMDI 160/4.5. Even mild asthma is primarily a
small-airway disease, hence this study’s outcome-measures
focus on those IOS parameters (R5–R20, AX) and respiratory
system model estimates (Rp, Cp) that reflect small-airway
mechanics.5,6 Note that in general, in all subjects, dosing
resulted in lower R5–R20, AX, and Rp values and higher Cp
values, consistent with improved small-airway mechanics
and therefore reduced airflow obstruction.3
Our data indicate that Symbicort acted slightly more
quickly than Advair during visit 2 (steroid-naïve condition).
This resembles previous studies comparing similar medications, such as Palmqvist et al,2 who studied 30 asthmatic
adults (28–73 years old) administered budesonide/formoterol
(160/4.5) or salmeterol/fluticasone (50/250) or placebo
using spirometric measurements (forced expiratory volume
in 1 second [FEV1]); onset of action, significantly different
from placebo, was reported by 3 minutes and by 15 minutes,
respectively. Our data also show that R5–R20 and Cp were
the more sensitive indicators of drug action.

However, after 4 weeks of dosing, the drugs’ effects
were muted, with Symbicort showing less action than
Advair. This is probably due to a 64% decrease in baseline AX (2.33–0.83 cmH2O/L) for the Symbicort group
over that period, whereas baseline AX decreased only 26%
(1.53–1.13 cmH2O/L) during the same time-frame in the
Advair group, ie, Symbicort produced greater long-term
improvement in small-airway mechanics than Advair. Box
plots of the individual AX values, grouped by medication,
are shown in Figure 5 to illustrate their statistical relationships over time. Note that 60 minutes postdose during the
randomization visits is roughly when the two groups (on
average) showed the most significant reduction in AX, while
during the final visits this nadir was reached slightly later,
at about 120 minutes.
Similarly, the change in baseline R5–R20, Cp, and
Rp between visits for the Symbicort group was 51% (0.259–
0.127 cmH2O/L/s), 101% (0.0674–0.1355 L/cmH2O), and
38% (0.6891–0.4265 cmH2O/L/s), respectively, versus 20%
(0.204–0.164 cmH2O/L/s), 37% (0.0840–0.1147 L/cmH2O),

Advair (final visit)

Symbicort (final visit)

0.5

0.5

0.45

0.45

0.4

0.4

0.35

0.35

0.3

P

0.3

P

0.25

0.25

0.2

0.2

0.15

0.15

0.1

0.1

0.05

0.05

0

0
5

20

40

60

120

Time (minutes)

240

5

20

40

60

120

240

Time (minutes)

Figure 2 t-test P-values of impulse oscillometry parameters (frequency-dependent resistance [R5–R20], *, and reactance [AX], ) at each time point after administration
of Advair or Symbicort during final visits compared to the patients’ baseline R5–R20 and AX values (0.164 cmH2O/L/second and 1.171 cmH2O/L, respectively, for Advair;
0.127 cmH2O/L/second and 0.833 cmH2O/L, respectively, for Symbicort) during the same visit (n = 15 for each group).
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Advair (randomization visit)

Symbicort (randomization visit)

0.9

0.01

0.8

0.009

0.7

0.008
0.007

0.6

0.006

0.5

P

0.4

P

0.3

0.005
0.004
0.003

0.2

0.002

0.1

0.001

0

20

5

40

60

120

0

240

5

20

40

60

120

240

Time (minutes)

Time (minutes)

Figure 3 t-test P-values of model estimates (peripheral airway resistance [Rp], ; peripheral airway compliance [Cp], ×) at each time point after administration of Advair
or Symbicort during randomization visits compared to the patients’ baseline Rp and Cp values (0.547 cmH2O/L/second and 0.084 L/cmH2O, respectively, for Advair;
0.689 cmH2O/L/second and 0.067 L/cmH2O, respectively, for Symbicort) during the same visit (n = 15 for each group).

and 14% (0.5474–0.4716 cmH2O/L/s), respectively, for the
Advair group. Figures 6–8 show box plots of the individual
R5–R20, Cp, and Rp values, respectively, grouped by medication, to illustrate their statistical relationships over time.
Comparing the various parameters over time, the other
findings can be summarized as follows:
• During the randomization visits, Symbicort produced greater bronchodilation at 5 minutes than
Advair. Since baseline AX = 2.33 cmH 2 O/L and
R5–R20 = 0.259 cmH 2O/L/second for the Symbicort group, and baseline AX = 1.53 cmH 2O/L and
R5–R20 = 0.204 cmH2O/L/second for the Advair group,
the Symbicort group had slightly worse lung function than
the Advair group, but at 5 minutes post-study drug, values
were AX = 0.643 cmH2O/L and R5–R20 = 0.113 cmH2O/L/
second for the Symbicort group, and AX = 1.12 cmH2O/L
and R5–R20 = 0.159 cmH2O/L/second for the Advair
group. The same implications can be gathered from the
Rp and Cp values at baseline for the Symbicort group
(0.689 cmH2O/L/second, 0.0674 L/cmH2O) and Advair
Advair (final visit)

0.9

P

group (0.547 cmH2O/L/second, 0.0840 L/cmH2O), and
at 5 minutes post-study drug for the Symbicort group
(0.397 cmH2O/L/second, 0.1340 L/cmH2O) and Advair
group (0.503 cmH2O/L/second, 0.1138 L/cmH2O).
• During the final visits, Symbicort produced lesser bronchodilation at 5 minutes than Advair. Since baseline
AX = 0.83 cmH2O/L and R5–R20 = 0.127 cmH2O/L/second
for the Symbicort group, and baseline AX = 1.13 cmH2O/L
and R5–R20 = 0.164 cmH2O/L/second for the Advair
group, the Symbicort group’s lung function had become
better than the Advair group’s lung function after 4 weeks
of treatment. So the Symbicort group had less room to
respond to bronchodilator/anti-inflammatory action. This
was corroborated by the smaller baseline Rp and larger
baseline Cp for the Symbicort group (0.426 cmH2O/L/
second, 0.1355 L/cmH2O) compared to the Advair group
(0.472 cmH2O/L/second, 0.1147 L/cmH2O).
• For the randomization visits, change in R5–R20 was
greater than change in AX at all-time points for both drugs.
However, for the final visits, this order was reversed.
Symbicort (final visit)

0.9

0.8

0.8

0.7

0.7

0.6

0.6

0.5

P

0.4

0.5
0.4

0.3

0.3

0.2

0.2

0.1

0.1
0

0
5

20

40

60

Time (minutes)

120

240

5

20

40

60

120

240

Time (minutes)

Figure 4 t-test P-values of model estimates (peripheral airway resistance [Rp], ; peripheral airway compliance [Cp], ×) at each time point after administration of Advair or
Symbicort during final visits compared to the patients’ baseline Rp and Cp values (0.472 cmH2O/L/second and 0.115 L/cmH2O, respectively, for Advair; 0.426 cmH2O/L/second
and 0.136 L/cmH2O, respectively, for Symbicort) during the same visit (n = 15 for each group).
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A

A

R5–R20 (cmH2O/L/s)

3.5

AX (cmH2O/L)

3
2.5
2
1.5

0.3
0.25
0.2
0.15
0.1
0.05

1

VR BL VR 60 min VF BL VF 120 min

0.5
0

Timepoint
VR BL

VR 60 min

VF BL

VF 120 min

B

Timepoint
R5-R20 (cmH2O/L/s)

0.5

B

4
3

0.2
0.1
0
VR BL VR 60 min

2

VF BL VF 120 min

Timepoint
Figure 6 Box plots of the individual impulse oscillometry frequency-dependent
resistance (R5–R20) values at two time points each during the randomization visits
(VR) and the final visits (VF) for (A) the Advair group and (B) the Symbicort group.
Abbreviation: BL, baseline.

1
0
VR 60 min

VF BL

VF 120 min

Timepoint
Figure 5 Box plots of the individual impulse oscillometry frequency-dependent
reactance (AX) values at two time points each during the randomization visits (VR)
and the final visits (VF) for (A) the Advair group and (B) the Symbicort group.
Abbreviation: BL, baseline.

Hence, long-term ICS/LABA use appears to fundamentally modify lung mechanics, resulting in less asynchronous behavior (improved time constants).
• For the randomization visits, the change in Cp was greater
than the change in Rp at all-time points for both drugs.
However, for the final visits, this order was reversed,
and the change in Rp was greater than the change in Cp
at all-time points for Advair and after 40 minutes for
Symbicort. It seems plausible to attribute these changes
to the anti-inflammatory effects of inhaled corticosteroids, particularly on the small-airway walls’ compliance.
This suggests that the respiratory system model provides
additional information regarding small-airway mechanics that is not conveyed by either R5–R20 or AX, although
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0.35
0.3
Cp (L/cmH2O)
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114

0.3
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0.2
0.15
0.1
0.05
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Timepoint

B
0.35
0.3
Cp (L/cmH2O)

AX (cmH2O/L)

5

0.4

0.25
0.2
0.15
0.1
0.05
VR BL VR 60 min VF BL VF 20 amin
Timepoint

Figure 7 Box plots of the individual peripheral airway compliance (Cp) values at two
time points each during the randomization visits (VR) and the final visits (VF) for
(A) the Advair group and (B) the Symbicort group.
Abbreviation: BL, baseline.
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Figure 10 Percent change in forced expiratory volume in 1 second (FEV1) up to
15 minutes and 3 hours with the combination of budesonide/formoterol (one or
two inhalations) (160/4.5 mg) compared with the combination salmeterol/fluticasone
(50/250 mg) and placebo. Reprinted from Lindberg et al,10 with permission from John
Wiley and Sons.
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Figure 8 Box plots of the individual peripheral airway resistance (Rp) values at two
time points each during the randomization visits (VR) and the final visits (VF) for
(A) the Advair group and (B) the Symbicort group.
Abbreviation: BL, baseline.

Rp and Cp seem less sensitive for detecting changes in
small-airway function. Moreover, Rp and Cp exhibit different aspects of the physiological effects of these drugs,
especially Symbicort, as seen in Figures 3 and 4.
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Figure 9 Mean forced expiratory volume in 1 second (FEV1) during the first
180 minutes after inhalation of budesonide/formoterol (pressurized metered-dose
inhaler [pMDI] 2 × 160/4.5 mg), salmeterol/fluticasone (pMDI 2 × 25/250 mg),
salbutamol (2 × 100 mg), or placebo (percentage increase from predrug value).
Copyright © 2001, Elsevier. Palmqvist M, Arvidsson P, Beckman O, Peterson S,
Lötvall J. Onset of bronchodilation of budesonide/formoterol vs salmeterol/
fluticasone in single inhalers. Pulm Pharmacol Ther. 2001;14(1):29–34.2
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• It appears that Symbicort produces a biphasic effect
on lung mechanics, ie, a quick-phase effect from about
5 to 30 minutes postdose, and a slow-phase effect from
about 50 minutes to over 240 minutes postdose. This can
be observed in both visits’ results for AX and R5–R20
(Figures 1 and 2), and for Rp and Cp (Figures 3 and 4).
Its cause is uncertain, although one may hypothesize that
formoterol has quite different pharmacodynamics than
budesonide. Previous studies investigating Symbicort’s
onset and/or duration of action2,7–11 were consulted. Data
presented by Palmqvist et al2 for asthmatic adults and by
Lindberg et al10 for chronic obstructive pulmonary disease
in adults (Figures 9 and 10) show an inflection in the change
from baseline FEV1 value occurring between 5 and 10 minutes and between 10 and 20 minutes, respectively, although
Figure 9 also shows an inflection in that time range for the
placebo group. Although neither paper suggested a possible biphasic action, their results and ours indicate that the
parameters’ inflections are due not to random variations
but some real physiological phenomenon.

Advair HFA MDI 115/21 produced a significant response
almost as early as Symbicort pMDI 160/4.5 after a single
dose in 12- to 45-year-old mild asthmatics, as determined
by IOS parameters and lung-model estimates: between 5
and 20 minutes versus less than 5 minutes, respectively.
This finding was consistent whether one considered R5–R20
or AX or Cp or Rp, which are all associated with peripheral
(small) airway mechanics.
Moreover, after 4 weeks of dosing, there was evidence
that both ICS/LABA combinations had produced significant
sustained improvement in peripheral airway parameters.
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This improvement resulted in diminished predose-to-postdose
differences, with Symbicort improving steady-state lung
function slightly more than Advair. It was somewhat surprising that there was no further improvement in small-airway
parameters when comparing single to steady-state dosing.
These findings could still have real-world clinical importance
in that the sustained amelioration of small-airway dysfunction
(decreased obstruction and improved compliance) noted in
these mild asthmatic subjects could lead to meaningful clinical benefits based on the documented association between
small-airway dysfunction and asthma control.3
Finally, a biphasic effect of Symbicort on lung function was observed that has heretofore been unnoted. Since
earlier studies’ data provide additional evidence that this is
a real phenomenon, further investigation as to its basis and
implications seems warranted.
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